• Publications
  • Influence
Extracorporeal antiaggregant pharmacotherapy in the treatment of acutely progressive forms of tuberculosis
TLDR
Few observations lead to a preliminary conclusion that this method positively affects the results of treatment for acutely progressive forms of tuberculosis, including those of Treatment for caseous pneumonia.
Bacteriological substantiation of the antituberculosis effect of immunotropic drug tubosan
TLDR
Use of tubosan for the treatment of 102 patients with drug-resistant destructive tuberculosis showed evident clinical-radiological involution process, with prospects of clinical recovery for 75% of patients.
Antituberculosis properties of methyldioxotetrahydropyrimidine sulfonisonicotinoyl hydrazide
TLDR
The study showed that MSH was efficient in complex therapy of tuberculosis patients allow for increased number of cases with drug resistant tuberculosis.
Extracorporeal immunopharmacological therapy in the treatment of patients with acutely progressing froms of pulmonary tuberculosis
TLDR
Investigations showed that this method sped up the regression of clinical and X-ray signs, during 1 to 2 months, and recovered the immune reactivity in 89% of patients, andvantages include a shorter time needed to arrest the endotoxicosis, a fuller and faster recovery of the main populations and sub-populations of lymphocytes and a less number of fatal outcomes.
Some specific features of drug resistance of Mycobacteria tuberculosis in patients with acutely progressive destructive forms of pulmonary tuberculosis
: A clear correlation has been found between the drug resistance of Mycobacterium tuberculosis (MBT) and the degree of immunodeficiency in 127 patients with acute destructive tuberculosis. The
Pathogenetic therapy for caseous pneumonia
TLDR
The use of a programme for stepwise pathogenetic therapy for caseous pneumonia by taking into account the identified variants decreased the number of fatal outcomes by 2.8 times in the study group of patients as compared with this parameter in the control group.
...
1
2
...